Searching for markers of nervous system autoimmune diseases
Studies biomarkers to help diagnose and monitor several nervous system autoimmune diseases in adults.
Plain-language title generated from the registry record
Registry title: Biomarkers in Autoimmune Disease of Nervous System
Key facts
- Where
- Wuhan, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with an autoimmune disease of the nervous system, such as NMOSD, MG, CIDP, IIM, MS, AE or MOGAD. Healthy people of the same sex and age can also join.
- Age
- 18 Years and older
- Sex
- All sexes
- Disease stage
- Clinical diagnosis of an autoimmune (autoinflammatory) disease of the nervous system, such as NMOSD, MG, CIDP, IIM, MS, AE or MOGAD.
Main reasons for not taking part
- Known history of primary immunodeficiency
- Severe infection of the central nervous system, lungs or elsewhere in the body
- Nerve damage from another cause, such as vasculitis, systemic lupus erythematosus or Sjögren's syndrome
- Vascular, hereditary metabolic, tumour or toxic diseases
- Pregnant or breastfeeding women
Read by machine on 12 November 2026.
Where in China
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaContact: Dai-shi Tian, DrTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Tongji Hospital
- Trial code
- NCT06502015
- Record updated
- 29 July 2026
- Original description
Neurological autoimmune diseases are a group of disorders characterized by the abnormal immune response attacking the nervous system, including the brain, spinal cord and peripheral nerves. These diseases exhibit high heterogeneity, diverse clinical presentations, and are challenging to diagnose and manage due to a lack of effective treatments. In this study, the investigators will recruit eight kinds of autoimmune diseases of nervous system including Neuromyelitis Optica Spectrum Disorder (NMOSD), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), idiopathic inflammatory myopathy (IIM), and multiple sclerosis (MS), autoimmune encephalitis (AE), Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD). Through this study, the investigators aim to discover biomarkers with high sensitivity, specificity, and stability, which can support early diagnosis, disease monitoring, and personalized treatment for neurological autoimmune diseases, thereby improving the quality of life and prognosis for patients.Read full original descriptionShow less
Biomarkers of Neurological Autoimmune Diseases
Neurological autoimmune diseases are a group of disorders characterized by the abnormal immune response attacking the nervous system, including the brain, spinal cord and peripheral nerves. These diseases exhibit high heterogeneity, diverse clinical presentations, and are challenging to diagnose and manage due to a lack of effective treatments. In this study, the investigators will recruit eight kinds of autoimmune diseases of nervous system including Neuromyelitis Optica Spectrum Disorder (NMOSD), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), idiopathic inflammatory myopathy (IIM), and multiple sclerosis (MS), autoimmune encephalitis (AE), Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD). Through this study, the investigators aim to discover biomarkers with high sensitivity, specificity, and stability, which can support early diagnosis, disease monitoring, and personalized treatment for neurological autoimmune diseases, thereby improving the quality of life and prognosis for patients.
Inclusion: Clinical diagnosis with autoinflammatory diseases of the nervous system, including: Neuromyelitis Optica Spectrum Disorder (NMOSD), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), idiopathic inflammatory myopathy(IIM), multiple sclerosis (MS), autoimmune encephalitis (AE), Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), ect al; sex and age-matched healthy individuals.
Exclusion: Known history of primary immunodeficiency (innate or acquired); Patients with severe central nervous system, pulmonary, or other systemic infections; Patients with secondary central nervous system demyelinating lesions, such as those caused by vasculitis, systemic lupus erythematosus, and Sjögren's syndrome; Patients with vascular (including hemorrhagic and ischemic), hereditary metabolic, neoplastic, or toxic diseases; Pregnant or lactating women.